Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers

Vaccine

Volumn 18, Issue 1-2, 1999, Pages 160-172

  Drabick, Joseph J ^a   Brandt, Brenda L ^a   Moran, Elizabeth E ^a   Saunders, Nancy B ^a   Shoemaker, David R ^a   Zollinger, Wendell D ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Immunogenicity; Intranasal; Meningococcus; Mucosal; Neisseria meningitidis; Vaccine

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; INTRANASAL DRUG ADMINISTRATION; MALE; MEMBRANE VESICLE; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINE PRODUCTION;

ADMINISTRATION, INTRANASAL; ADULT; AGED; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL VACCINES; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; STREPTOCOCCUS AGALACTIAE;

EID: 0033588487     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00216-9     Document Type: Article

References (33)

1. Jones D. Epidemiology of meningococcal disease in Europe and USA. Cartwright K. Meningococcal disease. 1995;147 John Wiley and Sons, Chichester, UK.
2. Caugant D.A., Froholm L.O., Bovre K., Holten E., Frasch C.E., Mocca L.F., Zollinger W.D., Selander R.K. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl. Acad. Sci. USA. 83:1986;4927-4931.
3. Scholten R.J., Poolman J.T., Valkenburg H.A., Bijlmer H.A., Dankert J., Caugant D.A. Phenotypic and genotypic changes in a new clone complex of Neisseria meningitidis causing disease in The Netherlands: 1958-1990. J. Infect. Dis. 169:1994;673-676.
4. Jones D.M., Kaczmarski E.B. Meningococcal infections in England and Wales: 1994. Commun. Dis. Rep. CDR Rev. 5:1995;R125-R130.
5. Martin D.R., Walker S.J., Baker M.G., Lennon D.R. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J. Infect. Dis. 177:1998;497-500.
6. Zollinger W.D. New and improved vaccines against meningococcal disease. Levine M.M., Woodrow G.C., Kaper J.B., Cobon G.S. New generation vaccines. 2nd ed. 1997;469 Marcel Dekker, New York.
7. Sierra G.V.G., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., Casanueva G.V., Rico C.O., Rodriguez C.R., Terry M.H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:1991;195-210.
8. de Moraes J.C., Perkins B.A., Camargo M.C., Hidalgo N.T., Barbosa H.A., Sacchi C.T., Landgraf I.M., Gattas V.L., Vasconcelos H. de G., et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 340:1992;1074-1078.
9. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., FrØholm L.O., et al. Production, characterization and control of MenB-vaccine 'Folkehelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:1991;67-80.
10. Bjune G., Hoiby E.A., Gronnesby J.K., Arnesen O., Fredriksen H.H., Halstensen A., et al. Effect of outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Lancet. 338:1991;1093-1096.
11. Boslego J., Garcia J., Cruz C., Zollinger W.D., Brandt B., Ruiz S., et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine. 13:1995;821-829.
12. Frasch C.E. Meningococcal vaccines: past, present and future. Cartwright K. Meningococcal disease. 1995;246 John Wiley and Sons, Chichester, UK.
13. Griffiss J.M. Mechanisms of host immunity. Cartwright K. Meningococcal disease. 1995;35 John Wiley and Sons, Chichester, UK.
14. Zollinger W.D., Kasper D.L., Veltri B.J., Artenstein M.S. Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect. Immun. 6:1972;835-851.
15. Poolman J.T., van der Ley P.A., Tommassen J. Surface structures and secreted products of meningococci. Cartwright K. Meningococcal disease. 1995;21 John Wiley and Sons, Chichester, UK.
16. Cruz C., Pavez G., Aguilar E., Garcia J., Ruiz S., Vicent P., et al. Serotype specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiol. Infect. 105:1990;119-126.
17. Zollinger W.D., Mandrell R.E., Griffiss J.M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J. Clin. Invest. 63:1979;836-848.
18. Saunders N.B., Shoemaker D.R., Brandt B.L., Moran E.E., Larsen T., Zollinger W.D. Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice. Infect. Immun. 67:1999;113-119.
19. Haneberg B., Dalseg R., Wedege E., Hoiby A., Haugen I.L., Oftung F., et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66:1998;1334-1341.
20. Zollinger W.D., Boslego J. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immunol. Methods. 46:1981;129-140.
21. Saunders N.B., Shoemaker D.R., Brandt B.L., Zollinger W.D. Confirmation of suspicious cases of meningococcal meningitis by PCR and ELISA. J. Clin. Microbiol. 35:1997;3215-3219.
22. Moran E.E., Brandt B.L., Zollinger W.D. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:1994;5290-5295.
23. Brandtzaeg P. Humoral immune response patterns of human mucosa: induction and relation to bacterial respiratory infections. J. Infect. Dis. 165:1992;s167-s176.
24. Walker R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine. 12:1994;378-400.
25. Russell M.W., Moldoveanu Z., White P.L., Sibert G.J., Mestecky J., Michalek S.M. Salivary, nasal, genital and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect. Immun. 64:1996;1272-1283.
26. Bergquist C., Johansson E.L., Lagergård T., Holmgren J., Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 65:1997;2676-2684.
27. Peeters C.C., Rumke H.C., Sundermann L.C., Rouppe van der Voort E.M., Meulenbelt J., Schuller M., et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine. 14:1996;1009-1015.
28. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129:1969;1327-1348.
29. Milagres L.G., Ramon S.R., Sacchi C.T., Melles C.E., Vieira V.S., Sato H. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:1994;4419-4424.
30. Mandrell R.E., Griffiss J.M., Macher B.A. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae and Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens: carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize cross-reacting antigens on LOS and human erythrocytes. J. Exp. Med. 168:1988;107-126.
31. Sierra G.V.G., Campa G.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:1991;195-210.
32. Scholten R.J.P.M., Kuipers B., Valkenburg H.A., Dankert J., Zollinger W.D., Poolman J.T. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whol-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41:1994;236-243.
33. Jones D.M., Borrow R., Fox A.J., Gray S., Cartwright K.A., Poolman J.T. The lipo-oligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog. 13:1992;219-224.